Synthesis of Three Key Impurities of Drug Dolutegravir: An Inhibitor of HIV-1 Integrase

References

• S. Min, I. Song, J. Borland, S. Chen, Y. Lou, T. Fujiwara, and S. C. Piscitelli, “Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers,” Antimicrobial Agents and Chemotherapy 54, no. 1 (2010): 254–8. doi:10.1128/AAC.00842-09.
   PubMed Web of Science ®Google Scholar
• Dorothy E. Dow, and John A. Bartlett, “Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV,” Infectious Diseases and Therapy 3, no. 2 (2014): 83–102. doi:10.1007/s40121-014-0029-7.
   PubMedGoogle Scholar
• Dolutegravir, DrugBank Accession Number DB08930, DRUGBABK online; accessed August 19, 2021, https://go.drugbank.com/drugs/DB08930.
   Google Scholar
• Dolutegravir Sodium Monograph for Professionals. Drugs.com; accessed August 19, 2021, https://www.drugs.com/monograph/dolutegravir.html.
   Google Scholar
• World Health Organization., 2019. World Health Organization model list of essential medicines: 21st list 2019. World Health Organization. https://apps.who.int/iris/handle/10665/325771. License: CC BY-NC-SA 3.0 IGO
   Google Scholar
• M. Daniyal, M. Akram, A. Hamid, A. Nawaz, K. Usmanghani, S. Ahmed, and L. Hameed, “Review: Comprehensive Review on Treatment of HIV,” Pakistan Journal of Pharmaceutical Sciences 29, no. 4 (2016): 1331–8. PMID: 27393456
   PubMed Web of Science ®Google Scholar
• M. S. Saag, R. T. Gandhi, J. F. Hoy, R. J. Landovitz, M. A. Thompson, P. E. Sax, D. M. Smith, C. A. Benson, S. P. Buchbinder, C. del Rio, et al, “Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel,” JAMA 324, no. 16 (2020): 1651–69. doi:10.1001/jama.2020.17025.
   PubMed Web of Science ®Google Scholar
• WHO recommends dolutegravir as preferred HIV treatment option in all populations. World Health Organization (Press release); accessed August 19, 2021, https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations.
   Google Scholar
• a) ICH Harmonized Triplicate Guideline: Impurities in New Drug Substances Q3A(R2), ICH Steering Committee, Step 4 of ICH process, 2006, accessed August 19, 2021, https://www.ema.europa.eu/en/ich-q3a-r2-impurities-new-drug-substances. b) International Conferences on Harmonization, Draft Revised Guidance on Impurities in New Drug Substances. Q3A(R). Federal Register. 65 (2000): 45085–90.
   Google Scholar
• a) Roy, “Pharmaceutical Impurities-a Mini-Review,” Aaps Pharmscitech 3, no. 2 (2002): 1–8.
   Google Scholar
  b) P. Pojashree, T. Parmila, S. M. Kumar, and G. P. S. Kumar, “A Review on Pharmaceutical Impurities and Its Importance in Pharmacy,” American Journal of PharmTech Research 9 (2019)76: –87. doi:10.46624/ajptr.2019.v9.i5.007.
   Google Scholar
• C. Satyanarayana, G. S. R. Anjaneyulu, D. V. L. Narasimha, K. M. Bushan, and A. Ravindra, “Novel Process for the Preparation of Dolutegravir and Pharmaceutically Acceptable Salts Thereof,” World Patent Application No: WO 2015/110897 A2, 30 July 2015.
   Google Scholar
• S. Sankareswaran, M. Mannam, V. Chakka, S. R. Mandapati, and P. Kumar, “Identification and Control of Critical Process Impurities: An Improved Process for the Preparation of Dolutegravir Sodium,” Organic Process Research & Development 20, no. 8 (2016): 1461–8. doi:10.1021/acs.oprd.6b00156.
   Web of Science ®Google Scholar
• M. R. Gudisela, P. Bommu, S. Navuluri, and N. Mulakayala, “Synthesis and Characterization of Potential Impurities of Dolutegravir: A HIV Drug,” ChemistrySelect 3, no. 25 (2018): 7152–5. doi:10.1002/slct.201800948.
   Web of Science ®Google Scholar
• S. Garrepalli, R. Gudipati, S. R. Amasa, K. Ravindhranath, and M. Pal, “Synthesis of Two Diastereomeric Impurities of a Fluorinated Antiretroviral Drug Dolutegravir,” Journal of Molecular Structure 1253 (2022): 132274. doi:10.1016/j.molstruc.2021.132274.
   Web of Science ®Google Scholar
• S. J. Saida, A. Manikandan, M. Kaliyaperumal, C. S. Rumalla, A. A. Khan, V. B. Jayaraman, R. Yanaka, and S. V. Rao, “Identification, Isolation and Characterization of Dolutegravir Forced Degradation Products and their Cytotoxicity Potential,” Journal of Pharmaceutical and Biomedical Analysis 174 (2019): 588–94. doi:10.1016/j.jpba.2019.06.022.
   PubMed Web of Science ®Google Scholar
• A. Jamshidi, F. M. Zonoz, and B. Maleki, “Synthesis and Characterization of a New Nano Ionic Liquid Based on Dawson-Type Polyoxometalate and its Application in the Synthesis of Symmetrical N,N′-Alkylidene Bisamides,” Polycyclic Aromatic Compounds 40, no. 3 (2020): 875–88. doi:10.1080/10406638.2018.1504094.
   Web of Science ®Google Scholar
• R. Tayebee, B. Maleki, F. M. Zonoz, R. M. Kakhki, and T. Kunani, “Mild, Efficient, and Environmentally Friendly Synthesis of Symmetrical N,N′-Alkylidenebisamides under Solvent-Free Conditions Catalyzed by H7[(P2W17O61)FeIII(H2O)],” RSC Advances 6, no. 25 (2016): 20687–94. doi:10.1039/C6RA01811D.
   Web of Science ®Google Scholar
• B. Maleki, F. M. Zonoz, and H. A. Akhlaghi, “An Efficient Synthesis of Symmetrical N,N′-Alkylidene bis-Amides Catalyzed by a Heteropolyacid,” Organic Preparations and Procedures International 47, no. 5 (2015): 361–7. doi:10.1080/00304948.2015.1066646.
   Web of Science ®Google Scholar